Skip to content
Menu

StoneX Maintains Speculative Buy on Intensity Therapeutics, Lowers Price Target to $8

Benzinga Newsdesk 2 weeks ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

StoneX analyst Robert Wasserman maintains Intensity Therapeutics (NASDAQ:INTS) with a Speculative Buy and lowers the price target from $12 to $8.

StoneX analyst Robert Wasserman maintains Intensity Therapeutics (NASDAQ:INTS) with a Speculative Buy and lowers the price target from $12 to $8.

Read at benzinga.com